Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$108.14 USD

108.14
553,507

-0.56 (-0.52%)

Updated Oct 21, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.

Kinjel Shah headshot

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

by Kinjel Shah

Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

by Kinjel Shah

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M

by Zacks Equity Research

AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.

Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline

by Zacks Equity Research

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.

Company News for Apr 30, 2021

by Zacks Equity Research

Companies in The News Are: MRK,KHC,SO,NOC

Kinjel Shah headshot

Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines

by Kinjel Shah

Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.

Merck (MRK) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of -14.11% and -5.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Healthcare ETFs on Radar As Q1 Earnings Unfold

by Sweta Killa

Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.

Why Merck (MRK) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

by Zacks Equity Research

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?

by Zacks Equity Research

AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.

David Borun headshot

Stocks Have First Down Week in Five on Tax Hike Fears

by David Borun

Stocks fall after a proposed rise in capital gains taxes, but make up most of the lost ground with a Friday rally.

Merck (MRK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.

Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $78.57, moving +1.17% from the previous trading session.

Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

by Zacks Equity Research

J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir

by Zacks Equity Research

Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development

by Kinjel Shah

FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.